ShEEP Request for BioPlex 3D System

ShEEP 请求 BioPlex 3D 系统

基本信息

项目摘要

We request funds to purchase a Bio-Plex 3D Microarray Suspension Array system for biomarker discovery and development at the VA Palo Alto. The requested Bio-Plex 3D will provide significant new capabilities through its ability to simultaneously measure up to 500 analytes per well, increased throughput, and reduced sample requirements. The proposed Bio-Plex 3D will enable analysis of commercially available or in-house developed antibody, multiplex cytokine, and other biomarker assays for investigation of a wide range of inflammatory diseases, cancer, metabolic diseases, and infectious diseases that affect millions of Veterans and civilians. The automated plate washer provides highly consistent washing of the Luminex beads, and is critical for obtaining highly consistent results both within and across experiments. All components included in our request and the attached GSA quote are integral parts of the Bio-Plex 3D System and will not be used independently. The VA Palo Alto research program is in great need of next-generation Luminex-based multiplexing capabilities for VA-funded research projects led by multiple VA Palo Alto-based investigators. The Bio-Plex 3D System will provide significant new multiplexing capabilities, throughput, and sensitivity as well as additional versatility for automated analysis compared to our existing instrument. Our current Luminex 200 System is 12 years old and frequently breaks down from almost daily use by many different VA Palo Alto labs. The requested instrument will provide key new capabilities for a large number of ongoing and future research projects the VA Palo Alto by increasing multiplexing capability, providing higher throughput, preserving limited tissue samples, minimizing intra-panel variation, and increasing the number of projects utilizing multiplex analysis. Similar instruments available at nearby Stanford University are already in high demand, typically saturated, and cannot accommodate the heavy usage by various VA users. Therefore, this instrument will bring significant benefits to the VA Palo Alto Research Community. Compared to similar instruments on the market, the Bio-Plex 3D System has an easier-to-use software system and significantly lower price. The new equipment will be placed in the common laboratory equipment room at the VA Palo Alto, maintained by the Robinson Lab, and available for use by all VA Palo Alto investigators. The Robinson Lab has the required technical expertise for and a track record of setting up, running and maintaining the shared Luminex 200 System at VA Palo Alto, and already established the shared equipment room space, support personnel, and financial plans for the requested instrument. A local advisory committee led by Dr. Robinson and consisting of VA Palo Alto users with a broad range of research interest and expertise will oversee the use and maintenance of the instrumentation. We envision long-term use of the equipment by the Major and Minor users on this grant proposal, in addition to new investigators whose research may require such assay systems. All users have well-established research programs with various sources of funding, including VA, NIH, and other grants, to support these projects. Research at VA Palo Alto is expanding efforts to decipher pathogenic mechanisms underlying diseases that affect Veterans and to develop novel diagnostics and therapeutics. Collaborations among VA Palo Alto laboratories are advancing discovery of next-generation biomarkers that will transform care for Veterans suffering from these diseases. Luminex-based multiplex biomarker analyses are significantly advancing identification of novel biological targets for diagnosis and treatment of these diseases. The requested Bio-Plex 3D System will not only enable collaborative studies at VA Palo Alto, but will also meet the increasing needs of additional projects requiring advanced multiplexing capabilities, throughput, and sensitivity in biomarker analyses.
我们申请资金购买Bio-Plex 3D微阵列悬浮阵列系统用于生物标记物的发现和

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William H Robinson其他文献

Immune tolerance of citrullinated peptides.
瓜氨酸肽的免疫耐受。
  • DOI:
    10.1038/s41584-024-01081-0
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Thomas;William H Robinson
  • 通讯作者:
    William H Robinson
Imatinib for the treatment of rheumatic diseases
伊马替尼用于治疗风湿性疾病
  • DOI:
    10.1038/ncprheum0465
  • 发表时间:
    2007-04-01
  • 期刊:
  • 影响因子:
    32.700
  • 作者:
    Ricardo T Paniagua;William H Robinson
  • 通讯作者:
    William H Robinson
Human peptidome display
人类肽组展示
  • DOI:
    10.1038/nbt.1888
  • 发表时间:
    2011-06-07
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    William H Robinson;Lawrence Steinman
  • 通讯作者:
    Lawrence Steinman

William H Robinson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William H Robinson', 18)}}的其他基金

BCCMA: Targeting Osteoarthritis Pain and Progression: Proteomics, RNASeq & Immunostaining to elucidate the immune pathotypes of OA
BCCMA:针对骨关节炎疼痛和进展:蛋白质组学、RNASeq
  • 批准号:
    10590409
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating the IL-4/13 Axis in Osteoarthritis
研究骨关节炎中的 IL-4/13 轴
  • 批准号:
    9891690
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Investigating the IL-4/13 Axis in Osteoarthritis
研究骨关节炎中的 IL-4/13 轴
  • 批准号:
    10092814
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Investigating the IL-4/13 Axis in Osteoarthritis
研究骨关节炎中的 IL-4/13 轴
  • 批准号:
    10438519
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Investigating the IL-4/13 Axis in Osteoarthritis
研究骨关节炎中的 IL-4/13 轴
  • 批准号:
    10553629
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis
在创伤后关节康复和骨关节炎中靶向肥大细胞
  • 批准号:
    10025268
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis
在创伤后关节康复和骨关节炎中靶向肥大细胞
  • 批准号:
    10672163
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Targeting Mast Cells in Post-Traumatic Joint Rehabilitation and Osteoarthritis
在创伤后关节康复和骨关节炎中靶向肥大细胞
  • 批准号:
    10284924
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci
肺腺癌抗癌抗体反应的大规模表征
  • 批准号:
    8664101
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Large-Scale Sequencing and Characterizing of Autoantibody Responses
自身抗体反应的大规模测序和表征
  • 批准号:
    8732967
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Sleep, telomere length and cardiorespiratory phenotype in 11-12 year old children: Cross-sectional Australian national population based study
11-12 岁儿童的睡眠、端粒长度和心肺表型:澳大利亚全国人口横断面研究
  • 批准号:
    nhmrc : 1115167
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Postgraduate Scholarships
Sleep, telomere length and cardiorespiratory phenotype in 11-12 year old children: Cross-sectional Australian national population based study
11-12 岁儿童的睡眠、端粒长度和心肺表型:澳大利亚全国人口横断面研究
  • 批准号:
    nhmrc : GNT1115167
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Postgraduate Scholarships
Development of an after-school programme to increase physical activity and dance skills in 11-12 year old girls
制定课后计划以提高 11-12 岁女孩的体育活动和舞蹈技能
  • 批准号:
    G0900844/1
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Protective and risk factors relating to 5-12 year old Victorian Aboriginal childrens health and social wellbeing
与 5-12 岁维多利亚州原住民儿童健康和社会福祉相关的保护因素和风险因素
  • 批准号:
    nhmrc : 629001
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
    NHMRC Postgraduate Scholarships
VAGAL TONE AND ATTENTION IN 8 TO 12-YEAR-OLD MALES EXPOSED TO OPIATES IN UTERO
子宫内接触阿片类药物的 8 至 12 岁男性的迷走神经张力和注意力
  • 批准号:
    3853760
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
RE-EVALUATION OF 10-12 YEAR OLD CHILDREN WITH CONGENITAL RUBELLA
对 10-12 岁先天性风疹儿童的重新评估
  • 批准号:
    3974273
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
RE-EVALUATION OF 10-12 YEAR OLD CHILDREN WITH CONGENITAL RUBELLA
对 10-12 岁先天性风疹儿童的重新评估
  • 批准号:
    4701728
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了